A research team has developed an innovative nanomotor-based strategy to improve immunotherapy for bladder cancer. The study, ...
Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...
The following is a summary of “GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis,” published in the February 2025 ...
During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...
A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled “Robust p53 phenotypes and ...
Researchers identify predictive markers of response to immunotherapy treatment in a study involving data from over 700 patients across six different cohorts. The study has significant relevance, ...
A new research paper was published in , Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells." ...
A new study suggests that a combination of radiation therapy and immune checkpoint inhibitors (ICIs) may offer a less ...
In a new book, Nafis Hasan writes about how America's ongoing "war on cancer" is going and points out factors that might be ...
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...
As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results